Pregnancy follow-up registry after Exablate for fibroids
Part of Cancer clinical trials.
This study keeps track of people’s pregnancy and birth outcomes after having Exablate treatment for symptomatic uterine fibroids. It may help doctors understand how safe and effective the treatment can be for future pregnancy plans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had uterine fibroids that caused symptoms
- You were treated with the Exablate system for your fibroids
- You are willing to join the registry (sign the consent form)
- You fit the Exablate device’s usual “indication” for symptomatic fibroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special contrast-enhanced ultrasound (CEUS and SHAPE) to take detailed images of uterine fibroids before and after a procedure called uterine artery embolization (UAE). It aims to help doctors better understand how fibroids respond to treatment.
This study collects health information from people with Fabry disease and specifically from pregnant people with Fabry disease. It helps researchers better understand the condition and how pregnancy affects health, using information you already experience in routine care.
This trial tests if a non-invasive treatment using electrical pulses can help the lining of the uterus recover faster after a surgical abortion. The goal is to improve future fertility and uterine health.
This trial tests a new device designed to safely remove uterine fibroids (benign growths in the uterus) during minimally invasive laparoscopic surgery while preserving your uterus. The goal is to see if this device makes the procedure faster and safer for women who want to keep their uterus.
This study tests whether a new model can predict pregnancy outcomes in women with uterine fibroids who want to conceive. It may help doctors decide the best treatment for you.
This study tests how well a long-term treatment using a relugolix combination tablet helps protect bone density in women who have uterine fibroids or endometriosis. It may help people who are at risk of bone thinning while receiving hormone-related symptom treatment.
Hear when a new Uterine Fibroid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.